|
DIDO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.89048776633172E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.00639505010258E-11 |
| Normal-vs-Stage2 |
4.53449999993083E-07 |
| Normal-vs-Stage3 |
1.0164979968863E-11 |
| Normal-vs-Stage4 |
1.34129995998933E-09 |
| Stage1-vs-Stage2 |
8.374200E-01 |
| Stage1-vs-Stage3 |
1.042380E-01 |
| Stage1-vs-Stage4 |
3.051000E-01 |
| Stage2-vs-Stage3 |
3.884000E-01 |
| Stage2-vs-Stage4 |
5.435000E-01 |
| Stage3-vs-Stage4 |
8.357400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.50510764646606E-14 |
| Normal-vs-AfricanAmerican |
2.383600E-03 |
| Normal-vs-Asian |
1.07969999996183E-06 |
| Caucasian-vs-AfricanAmerican |
1.200030E-01 |
| Caucasian-vs-Asian |
1.863360E-01 |
| AfricanAmerican-vs-Asian |
6.505600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.14749998392227E-09 |
| Normal-vs-Female |
1.9719781363392E-12 |
| Male-vs-Female |
4.007600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.58509880168845E-11 |
| Normal-vs-Age(41-60Yrs) |
1.65809999064237E-09 |
| Normal-vs-Age(61-80Yrs) |
1.93910443258005E-11 |
| Normal-vs-Age(81-100Yrs) |
1.50008999999507E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.809000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.188600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.299550E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.365200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.361230E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.888210E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.164300E-03 |
| Classical-VS-Follicular |
1.328630E-01 |
| Classical-VS-Other |
4.077400E-01 |
| Classical-VS-Normal |
1.11729958618412E-10 |
| Tall-VS-Follicular |
5.955500E-02 |
| Tall-VS-Other |
4.365800E-01 |
| Tall-VS-Normal |
7.1192052253366E-11 |
| Follicular-VS-Other |
8.401400E-01 |
| Follicular-VS-Normal |
7.86760001592057E-09 |
| Other-VS-Normal |
2.262100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.36810007766996E-10 |
| Normal-vs-N1 |
3.69240193975884E-11 |
| N0-vs-N1 |
1.253840E-01 |
|
|
